Trial Profile
Efficacy vedolizumab, infliximab, and adalimumab in patients with primary sclerosing cholangitis and inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Inflammatory bowel diseases; Primary sclerosing cholangitis
- Focus Therapeutic Use
- 18 Jul 2018 New trial record
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018